Main menu
Features
Webinars
Icon Library
Pricing
Testimonials
COVID VacTracker
Sign in
Sign up free

COVID-19 Vaccine & Therapeutics Tracker

See the latest updates for vaccine and therapeutic drug developments for COVID-19. Check back for regular updates!
New addition counters are reset every Monday by 11:59 PM ET. Last updated August 8, 2020 at 11:13 PM ET
Vaccines
164
TOTAL
41
IN HUMAN TRIALS
Therapeutic Drugs
358
+1
TOTAL
272
+1
IN HUMAN TRIALS
Activity FeedLive updates on vaccine and therapeutic drug developments
Russia becomes the first country to grant regulatory approval to a coronavirus vaccine, gam-COVID-vac, prior to its completion of clinical trials.
August 11, 2020
AstraZeneca’s therapeutic combination of monoclonal antibodies against the SARS-CoV-2 spike protein, AZD7442 , enters Phase 1 clinical trials.
August 11, 2020
Janssen Vaccine’s Ad26.COV2.S enters Phase 3 clinical trials, with an estimated enrollment of 60,000 participants worldwide.
August 10, 2020
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate, NVX-CoV2373 , for local production and commercialization in Japan.
August 7, 2020
Vaccination with NVX-CoV2373 was generally well-tolerated, induced neutralization antibody titers in 100% of participants, and elicited a robust cellular response in Novavax’s 131 participant Phase 1 clinical trial results.
August 4, 2020
Merck’s V591 , a SARS-CoV-2 vaccine candidate that uses an attenuated measles virus as a vector, enters Phase 1 clinical trials.
August 4, 2020
TMV-083 , a vaccine that uses a live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of SARS-CoV-2 enters Phase 1 clinical trials.
August 4, 2020
Eli Lilly and AbCellera’s antibody against the SARS-CoV-2 spike protein, LY3819253 , enter Phase 3 clinical trials in the United States.
August 4, 2020
Preliminary results have demonstrated that Aviptadil aided in rapid recovery from respiratory failure in the most critically ill patients with COVID-19 in an ongoing Phase 2/3 clinical trial sponsored by NeuroRx, Inc. and Relief Therapeutics.
August 3, 2020
A study published in Nature shows the SARS-CoV-2 vaccine Ad26.COV2.S elicits a strong immune response that protects against subsequent infection in a non-human primate model.
July 30, 2020
In a press release by Inovio, INO-4800 demonstrated the longest-term protection in non-human primates SARS-CoV-2 challenge model (13 weeks post-vaccination). The immunization also elicited antibodies that neutralize newer viral variants.
July 30, 2020
AZD1222 (ChAdOx1 nCoV-19) elicited a robust immune response in two animal models and prevented pneumonia in a non-human primate model of SARS-CoV-2 infection according to a publication in the journal Nature. However, there was no difference in nasal shedding between vaccinated and control animals.
July 30, 2020
Tocilizumab* failed to improved clinical status in patients with COVID-19 associated pneumonia, or reduced patient mortality in a randomized, double-blind, placebo-controlled phase 3 trial by Roche. The clinical trial program will continue to further explore the drug in other settings, including in combination with an antiviral.
July 29, 2020
The European Union purchases $73.9 million worth of Remdesivir* from Gilead, enough to treat 30,000 patients.
July 29, 2020
Health Canada authorizes the use of Remdesivir* in patients with severe COVID-19 symptoms.
July 28, 2020
BioNTech and Pfizer decide upon BNT162b2 as their candidate vaccine of choice moving forward in Phase 2/3 clinical trials. This study will include up to 30,000 participants at 120 sites worldwide.
July 27, 2020
MVC-COV1901 , a protein subunit vaccine developed by Medigen Vaccine Biologics Corp. enters Phase 1 clinical trials in Taiwan.
July 27, 2020
Arcturus Therapeutics’ RNA-based vaccine LUNAR-COV19 (ARCT-021) enters Phase 1/2 clinical trials in Singapore.
July 22, 2020
The antiviral drug Favipiravir* demonstrated faster viral clearance compared to the control arm and no severe adverse events in a press release by Glenmark Pharmaceuticals about their Phase 3 clinical trial of 150 individuals with mild to moderate COVID-19.
July 22, 2020
A deal securing up to 600 million doses of BNT162b2 was reached between The U.S. Government, Pfizer, and BioNTech with an assurance that Americans will receive the vaccine for free.
July 22, 2020
The University of Oxford and AstraZeneca’s AZD1222 (ChAdOx1 nCoV-19) showed an acceptable safety profile as well as elicited both a humoral and cellular immune response in people post-vaccination as demonstrated by a publication in The Lancet. These results support the continued evaluation of this vaccine in Phase III clinical trials.
July 20, 2020
Hospitalized patients who received inhaled Interferon beta-1a* (SNG001) had a 79% lower risk of developing severe disease and were more than twice as likely to recover from COVID-19 as those on placebo in a 101 person Phase II double-blind placebo-controlled trial by Synairgen plc.
July 20, 2020
CanSino’s Ad5-nCoV vaccine was safe and induced significant immune responses in the majority of recipients after a single immunization according to a publication in The Lancet.
July 20, 2020
The Unnamed Inactive Vaccine - Wuhan developed by The Wuhan Institute of Biological Products enters Phase 3 clinical trials in The United Arab Emirates.
July 18, 2020
The Imperial College’s self-amplifying RNA vaccine, LNP-nCoVsaRNA , moves on to Phase 2 clinical trials in The United Kingdom.
July 17, 2020
Over 100 top scientists and Nobel Laureates signed an open letter to the U.S. NIH calling for the production of unattenuated SARS-CoV-2 to test vaccine efficacy in controlled infection trials. The letter also calls for full transparency on vaccine development and trial participant diversity.
July 16, 2020
KBP-COVID-19 , a vaccine generated by using tobacco plants as bioreactors, enters Phase 1/2 clinical trials.
July 16, 2020
A new series of inactive viral vaccines, BBV152A, B, C , developed by Bharat Biotech International Limited enters Phase 1/2 clinical trials in the Republic of India.
July 15, 2020
Interim Phase 1 results for Modern’a mRNA-1273 vaccine were published in the New England Journal of Medicine, indicating that immunization induced anti–SARS-CoV-2 responses in all participants and no trial-limiting safety concerns were identified.
July 14, 2020
Moderna’s mRNA-1273 enter Phase III clinical trials in the United States of America with a targeted enrollment number of 30,000 participants.
July 14, 2020
The mRNA vaccine candidate BNT162b2 , developed by Biontech Pharmaceuticals and Pfizer has received ‘fast-track’ designation from the US FDA.
July 13, 2020
The anti-interleukin-6 receptor antibody Tocilizumab* was associated with lower mortality in mechanically ventilated patients suffering from COVID-19 in a single-center, small scale study published in the journal Clinical Infectious Disease. This reduction in mortality, however, came with a higher occurrence of bacterial infections.
July 11, 2020
The Unnamed Recombinant Vaccine - Anhui developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 2 clinical trials in China.
July 10, 2020
Johnson & Johnson’s non-replicating Adenvirus type-26 based vaccine, Ad26.COV2.S , enters Phase 1/2 clinical trials in The United States of America and Belgium.
July 9, 2020
A new DNA-based vaccine developed by AnGes Inc., AG0301-COVID19 , starts Phase 1/2 clinical trials in Japan.
July 9, 2020
Immunization with the repurposed vaccine Bacille Calmette-Guerin was shown to correlate with reduced mortality according to a study published by The Proceedings of the National Academy of Sciences of the United States of America. Clinical trial results will be required to corroborate these findings.
July 9, 2020
the mRNA-based vaccine mRNA-1273 , developed by Moderna, closes enrolment for its Phase 2 SARS-CoV-2 study.
July 8, 2020
The antiviral drug, Favipiravir* , was demonstrated to expedite the recovery of coronavirus patients in a double-blind placebo control clinical trial conducted by the Bangladesh Society of Medicine.
July 6, 2020
Cadila Healthcare Limited’s DNA plasmid vaccine, ZyCoV-D , enters Phase 1/2 clinical trials in The Republic of India.
July 4, 2020
The World Health Organization stops clinical trials involving (Hydroxy)Chloroquine* and combination lopinavir/ritonavir as the therapies fail to reduce COVID-19 mortality.
July 4, 2020
The inactive vaccine, CoronaVac , developed by Sinovac Biotech starts Phase III clinical trials in Brazil.
July 2, 2020
The anti-IL-6 antibody, Sarilumab* , was not beneficial in COVID-19 patients requiring mechanical ventilation according to Phase 3 clinical trial results released by Sanofi and Regeneron.
July 2, 2020
The mRNA vaccine candidate, BNT162b2 , developed by Biontech Pharmaceuticals and Pfizer was shown to be safe, tolerable, and immunogenic in preprint published results of their Phase 1/2 clinical trials.
July 1, 2020
Testing to resume on the antimalarial drug, (Hydroxy)Chloroquine* , to determine if it can prevent SARS-CoV-2 infection.
June 30, 2020
The DNA plasmid vaccine INO-4800 demonstrates Positive Interim Phase 1 Data according to a press release by Inovio Pharmaceuticals.
June 30, 2020
REGN10933+REGN10987 Combination Therapy , Regeneron Pharmaceuticals' anti-spike SARS-CoV-2 monoclonal antibodies enter Phase III clinical trials for prevention of SARS-CoV-2 infection.
June 30, 2020
No clinical benefit was observed from the use of Ritonavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
No clinical benefit was observed from the use of Lopinavir* in hospitalized COVID-19 patients during the University of Oxford’s RECOVERY trial.
June 29, 2020
The Ad5-nCoV vaccine, developed by CanSino Biologics Inc., gets approval for military use in China.
June 29, 2020
Remdesivir* , Gilead Sciences’ treatment found to have worked in COVID-19 clinical trials, will cost U.S. hospitals $3,120 for the typical patient with private insurance.
June 29, 2020
An Unnamed VLP Vaccine produced by Medicago Inc. enters Phase I clinical trials.
June 29, 2020
BBIBP-CorV , the inactive viral vaccine developed by the Beijing Institute of Biological Products and Sinopharm, was found to be safe and able to generate high titers of antibodies among participants in phase I and II clinical trials according to a company press release.
June 28, 2020
DUR-928 , a drug with a novel mechanism of action developed by Durect, enters Phase 2 clinical trials.
June 26, 2020
an mRNA vaccine, CVnCoV , developed by CureVac and Coalition for Epidemic Preparedness Innovations enters Phase 1 Clinical trials in Germany.
June 26, 2020
M5049 , a small molecule that blocks two innate immune sensors that detect single-stranded RNA from viruses, developed by EMD Serono and Merck enters Phase 2 Clinical trials.
June 26, 2020
The DNA plasmid vaccine, INO-4800 , developed by Inovio Pharmaceuticals in collaboration with International Vaccine Institute and Coalition for Epidemic Preparedness Innovations enters Phases 1/2 in the Republic of Korea.
June 25, 2020
GX-19 , a DNA vaccine expressing SARS-CoV-2 S-protein antigen developed by Genexine, Inc., enters Phase 1/2 clinical trials in the Republic of Korea.
June 24, 2020
A new Unnamed Recombinant Vaccine - Anhui developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. enters Phase 1 clinical trials in China.
June 24, 2020
News reports indicate that the Unnamed Inactive Vaccine - Wuhan developed by the Wuhan Institute of Biological Products and Sinopharm induced neutralizing antibodies in all vaccinated individuals, and that Phase III clinical trials will start June 23rd in both China and the United Arab Emirates.
June 23, 2020
AZD1222 (ChAdOx1 nCoV-19) starts Phase 1/2 clinical trials to assess safety, immunogenicity, and efficacy in adults with and without HIV in South Africa. This study is a partnership between the University of Witwatersrand, the University of Oxford, the Medical Research Council of South Africa, and the Bill and Melinda Gates Foundation.
June 23, 2020
Inhaled version of antiviral Remdesivir* to start human clinical trials in August according to Gilead Sciences.
June 22, 2020
The Unnamed Inactive Vaccine - Yunnan being developed by The Chinese Academy of Medical Sciences enters Phase II of clinical trials testing.
June 20, 2020
Gam-COVID-Vac , a new adenoviral-based vaccine developed by Gamaleya Research Institute, starts phase 1/2 clinical trials in Russia.
June 18, 2020
Preliminary results from the Oxford University RECOVERY trial in the United Kingdom indicates that low-dose dexamethasone, a type of Corticosteroid Therapy* , can reduce mortality by approximately one-third in COVID-19 patients on ventilators and by one-fifth of patients on oxygen.
June 16, 2020
A self-amplifying RNA-based vaccine candidate developed by Imperial College London in partnership with Morningside Ventures named COVAC 1 enters Phase 1/2 clinical trials.
June 15, 2020
The U.S. FDA revokes emergency authorization of (Hydroxy)Chloroquine* for treatment of COVID-19 amid growing evidence of ineffectiveness and the possibility of harmful side effects.
June 15, 2020
Preprint article in medRxiv indicates that Lenzilumab was safe and associated with improved clinical outcomes in high-risk COVID-19 patients with severe and critical pneumonia.
June 14, 2020
AstraZeneca has reached an agreement to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222 (ChAdOx1 nCoV-19) , to Germany, France, Italy, and the Netherlands, with deliveries starting by the end of 2020.
June 13, 2020
Sinovac announces no severe adverse events reported and that neutralizing antibodies developed 14 days after the vaccination in its preliminary results of phase 1/2 clinical trial for the Company’s COVID-19 vaccine candidate, CoronaVac .
June 13, 2020
June 12th - A new Unnamed Spike Protein Candidate developed by The University of Queensland enters Phase 1 clinical trials in Australia.
June 12, 2020
Preprint article in medRxiv indicates that the administration of Tocilizumab* is associated with rapid improvement in some clinical indices of those individuals not on ventilation, however, controlled clinical trials are needed to confirm its utility.
June 12, 2020
A novel protein subunit vaccine created by Vaxine and Medytox, COVAX-19 , enters Phase I clinical trials in the US.
June 11, 2020
Moderna moves forward with 100 ug dosage for Phase 3 clinical trial of mRNA-1273 and partners with Lonza to scale up manufacturing potential to generate between 500 million and 1 billion vaccine doses per year.
June 11, 2020
Remdesivir* shows clinical benefit in non-human primates infected with SARS-CoV2, as published in Nature.
June 9, 2020
A publication in the journal Cell indicates that administration of Beijing Institute of Biological Products and Sinopharm’s inactive vaccine, BBIBP-CorV , generates high neutralizing antibody titers and is safe, effective, and stable in numerous animals animal models, including non-human primates.
June 6, 2020
A Statement from the Chief Investigators of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial on (Hydroxy)Chloroquine* indicates no clinical benefit from its use in hospitalized patients with COVID-19.
June 5, 2020
Preprint article in medRxiv indicates that Bacille Calmette-Guerin vaccination was associated with reduced COVID-19 mortality in level 4:Do Not Travel countries when adjusted for a number of confounding variables.
June 5, 2020
The WHO resumes its COVID-19 (Hydroxy)Chloroquine* study after a publication in The Lancet that questioned the safety and efficacy of
June 3, 2020
Novavax secures upto $60M from the U.S. Department of Defense to support the production of their NVX-CoV2373 vaccine. The agreement includes a 2020 delivery of 10 million doses for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by the U.S. FDA.
June 4, 2020
A new study published in the New England Journal of Medicine indicates that prophylactic (Hydroxy)Chloroquine* did not prevent Covid-19 or confirmed SARS-CoV-2 infection within 4 days After high-risk or moderate-risk exposure.
June 3, 2020
The Brazilian Health Regulatory Agency approves human trials for Oxford University and AstraZeneca's AZD1222 (ChAdOx1 nCoV-19) . 2000 participants will be considered in Brazil through a study carried out by Oxford University and supported by AstraZeneca.
June 2, 2020
A report released indicates that the Phase 3 clinical trials for Moderna’s COVID-19 experimental vaccine, mRNA-1273 , will start in July with the enrollment of 30,000 individuals in a randomized, placebo-controlled trial.
June 2, 2020
Intravenous Immunoglobulin (IVIG; Octagam) therapy sponsored by Octapharma and Sharp HealthCare enters Phase IV clinical trials for COVID-19.
June 2, 2020
A new Unnamed Inactive Vaccine SARS-CoV-2 vaccine being developed by the Chinese Academy of Medical Sciences in collaboration with West China Second University Hospital and Yunnan Center for Disease Control and Prevention enters Phase 1/2.
June 2, 2020
Results released by Gilead indicate that in a Phase III trial, Remdesivir* treatment resulted in significantly greater clinical improvement versus standard of care treatment alone.
June 1, 2020
The immunosuppressive/antiviral Merimepodib* by ViralClear Pharmaceuticals enters Phase II clinical trials against COVID-19.
June 1, 2020
Emergent BioSolutions enters into a $628 million contract with the US government to boost manufacturing capacity for a COVID-19 vaccine.
June 1, 2020
mRNA-1273 , the joint vaccine initiative by Moderna, NIAID, and BARDA, enters Phase 2 clinical trials for COVID-19.
May 28, 2020
The spike protein subunit vaccine by Clover Biopharmaceutical, SCB-2019 , enters Phase 1 clinical trials against COVID-19.
May 28, 2020
France’s health ministry cancels the usage of (Hydroxy)Chloroquine* as a treatment to patients suffering severe forms of COVID-19.
May 27, 2020
The United Kingdom National Health Service follows suit behind The United States and Japan and authorizes the use of Remdesivir* for people with coronavirus infection after a publication in The New England Journal of Medicine indicates it can cut recovery time by about four days.
May 26, 2020
The World Health Organization suspends testing of (Hydroxy)Chloroquine* as a treatment for coronavirus after publication in The Lancet suggests drug could increase the risk of patients dying from COVID-19.
May 25, 2020
Novavax administrates the NVX-CoV2373 vaccine to the first participants in Phase 1 clinical trial. Phase 2 planned to begin following successful Phase 1 results. On May 11, Novavax secured a $388M grant from CEPI (a Bill & Melinda Gates Foundation-backed vaccine development coalition).
May 25, 2020
Sinovac Biotech Co. has received $15M in funding to advance the development of its Covid-19 vaccine candidate, CoronaVac .
May 25, 2020
CanSino Biologics’ Ad5-nCoV vaccine starts Phase 1/2 clinical trials in Canada against COVID-19 in collaboration with the Canadian Center for Vaccinology.
May 22, 2020
Phase 1 results for CanSino Biologics’ Ad5-nCoV vaccine published in The Lancet indicate it was tolerable and immunogenic in humans and warrants further clinical trials testing.
May 22, 2020
AstraZeneca/The University of Oxford vaccine AZD1222 (ChAdOx1 nCoV-19) starts Phase 2 / 3 clinical trials for COVID-19.
May 22, 2020
The INOPulse Delivery System by Bellerophon Therapeutics enters Phase 2 clinical trials for COVID-19.
May 22, 2020
AZD1222 (ChAdOx1 nCoV-19) , developed by the University of Oxford and licensed to AstraZeneca secures $1.2 billion backing from U.S Department of Health for accelerated development.
May 21, 2020
Publication in Nature Communications demonstrates robust antibody and cellular immunity elicited by Inovio's INO-4800 vaccine in preclinical models.
May 20, 2020
Inovio Pharmaceuticals press release announces positive interim Phase 1 data for their INO-4800 vaccine.
May 20, 2020
The elastase inhibitor MPH996* starts Phase 2 clinical trials for COVID-19 in Egypt.
May 20, 2020
Inovio Pharmaceutical's INO-4800 vaccine elicits robust immune response in preclinical models as shown in Nature Communications publication.
May 20, 2020
The C3 complement inhibitor AMY-101 sponsored by Amyndas Pharmaceuticals starts Phase 2 clinical trials for severe COVID-19.
May 20, 2020
Atea Pharmaceuticals' AT-527 , a novel modified guanosine nucleotide prodrug, starts Phase 2 for COVID-19.
May 20, 2020
ABX464 , a small molecule inhibitor of the cap binding complex sponsored by Abivax enters Phase 2 / 3 clinical trials for COVID-19.
May 19, 2020
Moderna press release announces positive interim Phase 1 data for its mRNA Vaccine, mRNA-1273 .
May 18, 2020
Health Canada approves human testing for CanSino Biologics's Ad5-nCoV vaccine. Trial will be conducted out of the Canadian Centre for Vaccinology at Dalhousie University.
May 18, 2020
EIDD-2801 , an oral nucleoside analog sponored by Ridgeback Biotherapeutics, enters Phase I clinical trials for COVID-19.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Ravulizumab into Phase 4 clinical trials.
May 18, 2020
The Cambridge University Hospitals NHS Foundation Trust-sponsored TACTIC-R study commences, bumping Baricitinib* into Phase 4 clinical trials.
May 18, 2020
Implicit Bioscience and the University of Washington’s anti-CD14 antibody, IC14 , enters Phase 2 clinical trials for COVID-19.
May 18, 2020
The anti-malarial Artemisinin enters Phase 2 clinical trials for COVID-19.
May 15, 2020
AV-COVID-19 is a new dendritic cell vaccine in Phases 1/2 clinical trials for COVID-19.
May 13, 2020
Ifenprodil , an NDMA inhibitor by Algernon Pharmaceuticals and Novatech starts Phase 2 / 3 clinical trials for COVID-19.
May 11, 2020
The vaccine for tuberculosis, Bacille Calmette-Guerin is now in consideration for COVID-19. Undergoing clinical Phases 3/4 trials.
April 20, 2020
Subscribe to Updates Enter your email to get alerted with major weekly updates.
Email
How would you describe yourself?
Vaccines
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
164
TOTAL

122 in preclinical development

41 in human trials

Vaccine Candidates Development Progress

Vaccine CANDIDATES

CoroFlu
DPX-COVID-19
PittCoVacc
AdCOVID
+117 unnamed
Preclinical
122
Phase I
35
Phase II
24
Phase III
11
Phase IV
3

Legend

Completed
In trials
Vaccine CandidatesClick on name for additional information
  ↓/↑Name  ↓/↑Organization  ↓/↑Technology  ↓/↑Stage  Countries  ↓/↑Clinical Trial #
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I/II
China
NCT04276896
Multiple Organizations
RNA-based vaccinePhase I/II/III
United States of America
NCT04283461
and 2 more
Multiple Organizations
Non-replicating viral vectorPhase I/II
China
Canada
NCT04313127
and 4 more
updated
Multiple Organizations
Inactivated virusPhase I/II/III
NCT04352608
and 3 more
Multiple Organizations
DNA-basedPhase I/II
Global
NCT04336410
and 1 more
Wuhan Institute of Biological Products,
Sinopharm
Inactivated virusPhase I/II/III
China
ChiCTR2000031809
and 1 more
Beijing Institute of Biological Products,
Sinopharm
Inactivated virusPhase I/II/III
China
ChiCTR2000032459
and 1 more
Multiple Organizations
DNA-basedPhase I
Canada
NCT04334980
Biontech SE,
Pfizer
RNA-based vaccinePhase I/II/III
Germany
EudraCT 2020-001038-36
and 3 more
Novavax,
Takeda
Protein subunitPhase I
United States of America
Australia
NCT04368988
Shenzhen Geno-Immune Medical Institute
Modified APCPhase I
China
NCT04299724
Unnamed
Saiba GmbH
Virus Like ParticlePreclinical Phase
Medicago Inc.
Virus Like ParticlePhase I
Global
NCT04450004
Unnamed
Imophoron Ltd,
Bristol University's Max Planck Centre
Virus Like ParticlePreclinical Phase
Unnamed
Doherty Institute
Virus Like ParticlePreclinical Phase
Unnamed
Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine,
Chile*
UnknownPreclinical Phase
Unnamed
Emergex Vaccines,
George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)*
UnknownPreclinical Phase
Unnamed
VBI Vaccines,
National Research Council of Canada
UnknownPreclinical Phase
Unnamed
SmartPharm Therapeutics,
Sorrento Therapeutics
UnknownPreclinical Phase
Unnamed
HaloVax (Voltron Therapeutics),
The Vaccine & Immunotherapy Center at the Massachusetts General Hospital
UnknownPreclinical Phase
Unnamed
ISR Immune System Regulation
UnknownPreclinical Phase
Unnamed
ImmunoPrecise
UnknownPreclinical Phase
Unnamed
Tulane University
UnknownPreclinical Phase
Unnamed
SK Biosciences
UnknownPreclinical Phase
Unnamed
Vir Biotechnology,
GSK
UnknownPreclinical Phase
Unnamed
Precision Vaccines Program at Boston Children's Hospital
UnknownPreclinical Phase
Kentucky BioProcessing,
Inc.
Protein subunitPhase I/II
NCT04473690
Unnamed
Universite Laval
UnknownPreclinical Phase
Unnamed
Covaxx
UnknownPreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
RNA-based vaccinePreclinical Phase
Unnamed
University of Tokyo,
Daiichi-Sankyo
RNA-based vaccinePreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Arcturus Therapeutics, Inc.,
Duke-NUS
RNA-based vaccinePhase I/II
United States of America
Republic of Singapore
NCT04480957
Imperial College London,
Morningside Ventures
RNA-based vaccinePhase I/II
United Kingdom
China
IRAS-Number: 279315
and 1 more
CureVac AG,
Coalition for Epidemic Preparedness Innovations (CEPI)
RNA-based vaccinePhase I
NCT04449276
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
BIOCAD
RNA-based vaccinePreclinical Phase
Unnamed
GeneOne Life Science,
Houston Methodist
RNA-based vaccinePreclinical Phase
Unnamed
Zydus Cadila
Replicating viral vectorPreclinical Phase
UnnamedMultiple Organizations
RNA-based vaccinePreclinical Phase
Unnamed
Sanofi Pasteur,
Translate Bio
RNA-based vaccinePreclinical Phase
Multiple Organizations
Replicating viral vectorPhase I
NCT04497298
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
ExpreS2ion
Protein subunitPreclinical Phase
Unnamed
WRAIR,
USAMRIID
Protein subunitPreclinical Phase
Unnamed
National Institute of Infectious Disease,
Japan
Protein subunitPreclinical Phase
Unnamed
Osaka University / BIKEN / National Institutes of Biomedical Innovation,
Japan
Protein subunitPreclinical Phase
Clover Biopharmaceuticals
Protein subunitPhase I
China
NCT04405908
Unnamed
Vaxil Bio
Protein subunitPreclinical Phase
Unnamed
Biological E Ltd
Protein subunitPreclinical Phase
Unnamed
AJ Vaccines
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Generex,
EpiVax
Protein subunitPreclinical Phase
Unnamed
EpiVax,
University of Georgia
Protein subunitPreclinical Phase
PittCoVacc
University of Pittsburgh
Protein subunitPreclinical Phase
United States of America
Unnamed
University of Cambridge,
DIOSynVax
Protein subunitPreclinical Phase
UnnamedMultiple Organizations
Protein subunitPreclinical Phase
Unnamed
Sanofi Pasteur,
GSK
Protein subunitPreclinical Phase
Unnamed
Heat Biologics (Zolovax),
University of Miami
Protein subunitPreclinical Phase
Multiple Organizations
Protein subunitPhase I
ACTRN12620000674932
and 1 more
Unnamed
Baylor College of Medicine
Protein subunitPreclinical Phase
Unnamed
iBio,
CC-Pharming
Protein subunitPreclinical Phase
Unnamed
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunitPreclinical Phase
Unnamed
VIDO-InterVac,
University of Saskatchewan
Protein subunitPreclinical Phase
Unnamed
Flow Pharma
Protein subunitPreclinical Phase
Unnamed
OncoGen
Protein subunitPreclinical Phase
Unnamed
MIGAL Galilee Research Institute
Protein subunitPreclinical Phase
Unnamed
University of Alberta
Protein subunitPreclinical Phase
DPX-COVID-19
IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority,
Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada
Protein subunitPreclinical Phase
Canada
Unnamed
GeoVax,
BravoVax
Non-replicating viral vectorPreclinical Phase
updated
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
NCT04436276
and 1 more
Unnamed
ReiThera
Non-replicating viral vectorPreclinical Phase
Unnamed
ImmunityBio,
NantKwest
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
AdCOVID
Altimmune,
University of Alabama at Birmingham
Non-replicating viral vectorPreclinical Phase
United States of America
Unnamed
Greffex
Non-replicating viral vectorPreclinical Phase
Unnamed
Vaxart,
Emergent BioSolutions
Non-replicating viral vectorPreclinical Phase
Unnamed
Centro Nacional Biotecnologia (CNB-CSIC),
Spain
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Manitoba
Non-replicating viral vectorPreclinical Phase
Unnamed
DZIF - German Center for Infection Research
Non-replicating viral vectorPreclinical Phase
Unnamed
Tonix Pharma,
Southern Research
Non-replicating viral vectorPreclinical Phase
Unnamed
BIOCAD,
IEM
Non-replicating viral vectorPreclinical Phase
Unnamed
IAVI,
Batavia
Non-replicating viral vectorPreclinical Phase
Unnamed
The University of Hong Kong
Non-replicating viral vectorPreclinical Phase
Unnamed
University of Western Ontario
Non-replicating viral vectorPreclinical Phase
Unnamed
Valneva,
Dynavax*
Inactivated virusPreclinical Phase
Unnamed
Sinovac,
Dynavax
Inactivated virusPreclinical Phase
UnnamedMultiple Organizations
Inactivated virusPreclinical Phase
Unnamed
Codagenix,
Serum Institute of India
Inactivated virusPreclinical Phase
CoroFluMultiple Organizations
Inactivated virusPreclinical Phase
United States of America
Republic of India
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
OPENCORONA - Cobra Biologics,
Karolinska Institute
DNA-basedPreclinical Phase
AnGes, Inc.,
Japan Agency for Medical Research and Development
DNA-basedPhase I/II
NCT04463472
Zydus Cadila,
Cadila Healthcare Limited
DNA-basedPhase I/II
CTRI/2020/07/026352
UnnamedMultiple Organizations
DNA-basedPreclinical Phase
Unnamed
BioNet Asia
DNA-basedPreclinical Phase
Unnamed
University of Waterloo
DNA-basedPreclinical Phase
Multiple Organizations
RepurposedPhase III/IV
NCT04357028
and 2 more
Immunitor LLC
Inactivated virusPhase I/II
Canada
NCT04380532
Aivita Biomedical,
Inc.
Modified APCPhase I/II
United States of America
NCT04386252
Multiple Organizations
Non-replicating viral vectorPhase I/II/III
United Kingdom
NCT04324606
and 6 more
Multiple Organizations
RepurposedPhase III/IV
Global
NCT04328441
and 22 more
Multiple Organizations
Inactivated virusPhase I/II
China
NCT04412538
and 1 more
Multiple Organizations
Protein subunitPhase I
Global
NCT04428073
and 1 more
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation,
Acellena Contract Drug Research and Development
Non-replicating viral vectorPhase I/II
Russia
NCT04437875
and 1 more
Immunovative Therapies, Ltd.,
Mirror Biologics, Inc.
OtherPhase I/II
United States of America
NCT04441047
Multiple Organizations
RepurposedPhase III
Canada
United Kingdom
NCT04442048
Altimmune,
Inc.
RepurposedPhase II
United States of America
NCT04442230
Genexine,
Inc.
DNA-basedPhase I/II
NCT04445389
Bandim Health Project
RepurposedPhase IV
Republic of Guinea-Bissau
NCT04445428
Inmunotek S.L.,
BioClever 2005 S.L.
RepurposedPhase III
Mexico
NCT04452643
Fundació Institut Germans Trias i Pujol
RepurposedPhase N/A
NCT04453488
Bharat Biotech International Limited,
Indian Council of Medical Research
Inactivated virusPhase I/II
Republic of India
NCT04471519
Medigen Vaccine Biologics Corp.
Protein subunitPhase I
Taiwan
NCT04487210
Multiple Organizations
Protein subunitPhase I/II
China
NCT04445194
and 1 more
Multiple Organizations
RNA-based vaccinePhase I
China
ChiCTR2000034112
Merck Sharp & Dohme Corp.
Replicating viral vectorPhase I
United States of America
NCT04498247
Therapeutic Drugs
Visualized development progress and additional information on preclinical and human clinical vaccine candidates against COVID-19.
358
+1
TOTAL

87 in preclinical development

272 in human trials

Drug Candidates Development Progress

Drug CANDIDATES

Therapeutic Plasma Exchange
Bivalirudin
Bromhexine*
Ledipasvir*
Sofosbuvir*
Doxycycline*
N-acetylcysteine
Pacritinib
Bucillamine
Rosuvastatin*
Broncho-Vaxom
Prasugrel
XC221
Atazanavir*
Melatonin
Dipyridamole
Olokizumab
TD139
BIO101
Daclatasvir*
Secukinumab
Acetylsalicylic acid
INM005
Bardoxolone methyl
Atorvastatin
NA-831*
Lactoferrin
RPH-104
PTC299
RESP301
BDB-001
Ambrisentan*
REGN10933+REGN10987 Combination Therapy
Opaganib
Povidone-Iodine
AMY-101
F-652
Poractant alfa
Apremilast*
Nelfinavir*
Razuprotafib*
Sulfamethoxazole*
AT-527
Icatibant*
Disulfiram
Trimethoprim*
Ramelteon
Cenicriviroc*
Ebselen
Decitabine
Fluvoxamine
CERC-002
Axatilimab
Genistein
ATI-450
Clofazimine
EC-18
Desidustat
Prostacyclin
Infliximab
Vadadustat
Monalizumab
OP-101
Nangibotide
ANG-3777
Ibudilast
Itolizumab
Atovaquone
Pamrevlumab
Enzalutamide
XAV-19
PB1046
Chlorhexidine
Crizanlizumab
Abivertinib
Duvelisib
Ibrutinib
DB-001
Pyronaridine
LAM-002A
M5049
DUR-928
C21
Autologous Adipose-derived Stem Cells
Maraviroc*
Tramadol
Pentoxifylline
CAStem
Alpha-1 antitrypsin
Radiation Therapy
Brequinar
Rapamycin
Lanadelumab
Sildenafil
TL-895
RAPA-501-Allo cells
Ulinastatin
Abatacept
Autologous Non-Hematopoietic Peripheral Blood Stem Cells
AZD7442
BAT2020
STI-1499
Ampion
BRII-196
SAR443122
JS016
CK0802
SCTA01
TRV027
PSC-04
TAK-671
NT-17
MK-5475
CPI-006
TY027
SAB-185
PLX-PAD
Astrostem-V
VIR-7831 and VIR-7832
REGN3048-3051
Polyclonal hyperimmune globulin
AmnioBoost
SNG001
DIBI
GP1681
Brilacidin
+75 unnamed
Preclinical
85
Phase I
79
Phase II
198
Phase III
107
Phase IV
40

Legend

Completed
In trials
Drug CandidatesClick on name for additional information
  ↓/↑Name  ↓/↑Organization  ↓/↑Technology  ↓/↑Stage  Countries  ↓/↑Clinical Trial #
Washington University School of Medicine
OtherPhase II
NCT04342663
University of Alabama at Birmingham
OtherPhase II
NCT04338126
and 1 more
Radboud Universit,
National University of Ireland, Galway, Ireland
OtherPhase IV
NCT04335786
and 1 more
I-Mab Biopharma Co. Ltd.
AntibodiesPhase I/II
NCT04341116
Humanigen,
Inc.
AntibodiesPhase III
NCT04351152
GlaxoSmithKline
AntibodiesPhase III
NCT04376684
Multiple Organizations
OtherPhase II
NCT04387240
and 2 more
Multiple Organizations
OtherPhase II/III/IV
NCT04355936
and 8 more
Multiple Organizations
OtherPhase I/II/III/IV
NCT04261517
and 107 more
Multiple Organizations
AntiviralsPhase II/III
NCT04292730
and 24 more
Multiple Organizations
AntiviralsPhase I/II/III/IV
NCT04303299
and 45 more
Multiple Organizations
AntiviralsPhase III
NCT04261907
and 1 more
Multiple Organizations
AntiviralsPhase II/III/IV
NCT04303299
and 30 more
Multiple Organizations
AntiviralsPhase III/IV
ChiCTR2000029541
and 4 more
Multiple Organizations
AntibodiesPhase I/II/III/IV
NCT04357808
and 13 more
Multiple Organizations
AntibodiesPhase II/III/IV
NCT04317092
and 50 more
Multiple Organizations
AntibodiesPhase II/III
NCT04275414
and 3 more
Multiple Organizations
AntibodiesPhase II
NCT04268537
and 8 more
Multiple Organizations
OtherPhase I/II/III
NCT04268537
and 4 more
CytoDyn
AntibodiesPhase II
NCT04343651
and 2 more
Multiple Organizations
AntibodiesPhase II/III
NCT04322188
and 3 more
Multiple Organizations
AntibodiesPhase II/III
NCT04288713
and 3 more
Multiple Organizations
AntibodiesPhase II/III
NCT04362813
and 3 more
Swedish Orphan Biovitrum
AntibodiesPhase II/III
NCT04324021
Tang-Du Hospital
AntibodiesPhase I/II
NCT04275245
Eli Lilly and Company
AntibodiesPhase II
NCT04342897
Multiple Organizations
AntibodiesPhase II/III
NCT04333420
Multiple Organizations
AntibodiesPhase I/II/III
NCT04321421
and 84 more
Multiple Organizations
AntibodiesPhase II/III/IV
NCT04261426
and 10 more
Multiple Organizations
AntiviralsPhase I/II/III/IV
NCT04303299
and 48 more
BioCryst Pharmaceuricals
AntiviralsPhase I
NCT03891420
Mianyang Central Hospital
AntiviralsPhase IV
ChiCTR2000030535
Ascletis Pharmaceuticals Co., Ltd.,
The Ninth Hospital of Nanchang
AntiviralsPhase IV
NCT04291729
Roche,
The First Affiliated Hospital of Zhejiang University Medical School
AntiviralsPhase N/A
ChiCTR2000029544
and 1 more
Multiple Organizations
AntiviralsPhase I/IV
NCT04252885
and 6 more
Multiple Organizations
AntiviralsPhase III
ChiCTR2000029468
and 3 more
He'nan Sincere Biotechnology Co., Ltd,

AntiviralsPhase N/A
ChiCTR2000030487
and 3 more
Multiple Organizations
AntiviralsPhase I/III/IV
NCT04303299
and 6 more
Multiple Organizations
AntiviralsPhase I/II/III
NCT04356677
and 5 more
Polyclonal hyperimmune globulinMultiple Organizations
AntibodiesPreclinical Phase
Unnamed
Celltrion
AntibodiesPreclinical Phase
REGN3048-3051
Regeneron
AntibodiesPreclinical Phase
Unnamed
Celltrion
AntibodiesPreclinical Phase
Unnamed
Kamada,
Kedrion Biopharma
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
VIR-7831 and VIR-7832Multiple Organizations
AntibodiesPreclinical Phase
Unnamed
Eli Lilly,
Ab-Cellera (NIH Vaccines Research Center)
AntibodiesPreclinical Phase
Bukwang Pharmaceutical
AntiviralsPhase II
NCT04347915
Athersys,
Inc.
Cell-based therapiesPhase II/III
NCT04367077
Multiple Organizations
Cell-based therapiesPhase I/II
NCT04365101
Unnamed
Erasmus MC,
Utrecht University
AntibodiesPreclinical Phase
Unnamed
ImmunoPrecise Antibodies
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
UnnamedMultiple Organizations
AntibodiesPreclinical Phase
Unnamed
Distributed Bio
AntibodiesPreclinical Phase
Unnamed
Chelsea and Westminster Hospital,
Imperial College London
AntibodiesPreclinical Phase
Unnamed
Vanderbilt Vaccine Center,
AstraZeneca
AntibodiesPreclinical Phase
Unnamed
Medicago,
Laval University's Infectious Disease Research Centre
AntibodiesPreclinical Phase
Unnamed
FairJourney Biologics,